Author:
Nolfi-Donegan Deirdre,Konar Monica,Vianzon Vianca,MacNeil Jessica,Cooper James,Lurie Perrianne,Sedivy Judi,Wang Xin,Granoff Dan M.,McNamara Lucy
Publisher
Centers for Disease Control and Prevention (CDC)
Subject
Infectious Diseases,Microbiology (medical),Epidemiology
Reference15 articles.
1. An international consensus approach to the management of atypical hemolytic uremic syndrome in children.;Loirat;Pediatr Nephrol,2016
2. Alexion Pharmaceuticals, Inc. Soliris. Revised 1/2016 [package insert] [cited 2016 Dec 2]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125166s417lbl.pdf
3. Alexion Pharmaceuticals, Inc. Soliris REMS (Risk Evaluation and Mitigation Strategy) [cited 2017 Jul 23]. http://www.solirisrems.com
4. Post-eculizumab meningococcaemia in vaccinated patients.;Lebel;Clin Microbiol Infect,2018
5. Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome.;Cullinan;Pediatrics,2015
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献